Comparison of Outcomes Following a Switch from a Brand to an Authorized vs. Independent Generic Drug

被引：0
|
作者：
Hansen, Richard A. [1 ]
Qian, Jingjing [1 ]
Berg, Richard [2 ]
Linneman, James [2 ]
Seoane-Vazquez, Enrique [3 ]
Dutcher, Sarah [4 ]
Raofi, Saeid [4 ]
Peissig, Peggy [2 ]
机构：
[1] Auburn Univ, Dept Hlth Outcomes Res & Policy, Harrison Sch Pharm, Auburn, AL 36849 USA
[2] Marshfield Clin Res Fdn, Biomed Informat Res Ctr, Marshfield, WI USA
[3] Massachusetts Coll Pharm & Hlth Sci, Int Ctr Pharmaceut Econ & Policy, Boston, MA USA
[4] US FDA, Off Gener Drugs, Silver Spring, MD USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2016年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1036
引用
收藏
页码：602 / 603
页数：2
相关论文
共 50 条
  • [21] Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study
    Anoushka Dasi
    Donna N. Kring
    Bhavani Selvaraj
    Patricia Morgan
    Christopher Gerity
    Eric E. Morgan
    Ramkumar Krishnamurthy
    Rajesh Krishnamurthy
    Pediatric Radiology, 2023, 53 : 2622 - 2632
  • [22] Safety of Overnight Switch from Brand-Name to Generic Levetiracetam
    Vari, Maria Stella
    Pinto, Francesca
    Mencaroni, Elisabetta
    Giudizioso, Giovanna
    Minetti, Carlo
    La Neve, Angela
    Francavilla, Tiziana
    Piccioli, Marta
    Striano, Salvatore
    del Gaudio, Luigi
    Tovo, Pierangelo
    Striano, Pasquale
    Verrotti, Alberto
    CLINICAL DRUG INVESTIGATION, 2016, 36 (01) : 87 - 91
  • [23] Safety of Overnight Switch from Brand-Name to Generic Levetiracetam
    Maria Stella Vari
    Francesca Pinto
    Elisabetta Mencaroni
    Giovanna Giudizioso
    Carlo Minetti
    Angela La Neve
    Tiziana Francavilla
    Marta Piccioli
    Salvatore Striano
    Luigi del Gaudio
    Pierangelo Tovo
    Pasquale Striano
    Alberto Verrotti
    Clinical Drug Investigation, 2016, 36 : 87 - 91
  • [24] Generic Vs. Brand-name Fluticasone-Salmeterol in the Prevention of COPD Exacerbations
    Feldman, W. B.
    Kesselheim, A.
    Avorn, J.
    Wang, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [25] Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D
    Dusetzina, Stacie B.
    Sarpatwari, Ameet
    Carrier, Michael A.
    Hansen, Richard A.
    Keating, Nancy L.
    Huskamp, Haiden A.
    JAMA INTERNAL MEDICINE, 2021, 181 (12) : 1605 - 1611
  • [26] Fetal and Maternal Outcomes Following Cesarean Hysterectomy: A Comparison of General vs. Regional Anesthesia
    Hoffman, Mallory
    Hallett-Voss, Carrie
    Devaiah, Ganga
    Voss, Deward
    OBSTETRICS AND GYNECOLOGY, 2016, 127 : 99S - 99S
  • [27] Virtual vs. human influencer: Effects on users' perceptions and brand outcomes
    De Cicco, Roberta
    Iacobucci, Serena
    Cannito, Loreta
    Onesti, Gianni
    Ceccato, Irene
    Palumbo, Riccardo
    TECHNOLOGY IN SOCIETY, 2024, 77
  • [28] The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
    Toenders, Wil
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [29] Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011
    Cheng, Ning
    Banerjee, Tannista
    Qian, Jingjing
    Hansen, Richard A.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2017, 57 (03) : 341 - 348
  • [30] Adverse Drug Reaction Reports Following a "Brand Switch". The New Zealand experience
    Braund, R.
    Tatley, M.
    DRUG SAFETY, 2018, 41 (11) : 1193 - 1194
12345